{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:35Z","timestamp":1787020355628,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although biologic agents have revolutionized the medical management of severe ulcerative colitis (UC), there is considerable controversy regarding adverse effects of vedolizumab on surgical outcomes. We evaluated 30-day postoperative morbidity in UC patients undergoing abdominal colectomy (AC) treated with vedolizumab before surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From 2007 to 2017, 285 patients were enrolled in prospectively maintained database evaluating the role of clinical, serologic markers with clinical phenotypes in UC. The patients treated with vedolizumab within 12\u2009weeks of AC was queried, then matched 1:3:3 into 3 preoperative treatment groups based on age, gender and surgical treatment of UC; ileal pouch-anal anastomosis (IPAA) with ileostomy vs total colectomy with end stoma: a) vedolizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925); b) anti-tumor necrosis factor (anti-TNF) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200974); and c) no biologics (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200954). Thirty-day postoperative complications among patient groups were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 3 patient groups were well-matched in other characteristics including disease duration, disease extent, medication history and preoperative serological data. There were no significant differences in the overall incidence of postoperative complications among patients treated preoperatively with vedolizumab, anti-TNFs, or no biologics (44% vs. 45% vs. 37%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.67). Although there was no significant difference between patient cohorts in infectious complications (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.20), postoperative ileus (POI) was significantly more common among the vedolizumab group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; 36%) compared to anti-TNF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912; 16%) or no biologics (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095; 9%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Multivariable analysis showed that vedolizumab treatment prior to surgery was an independent risk factor for POI (OR: 5.16, 95% CI; 1.71\u201315.52;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although preoperative vedolizumab exposure did not influence the rate of overall 30-day postoperative complications, vedolizumab tends to increase incidence of POI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12893-020-00698-8","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T08:02:52Z","timestamp":1583395372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study"],"prefix":"10.1186","volume":"20","author":[{"given":"Jeong Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zaghiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lightner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"issue":"2","key":"698_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SLA.0b013e3181e61df5","volume":"252","author":"DW Jones","year":"2010","unstructured":"Jones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010;252(2):307\u201312.","journal-title":"Ann Surg"},{"issue":"18","key":"698_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713\u201325.","journal-title":"N Engl J Med"},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2482-14-23","volume":"14","author":"E Frostbert","year":"2014","unstructured":"Frostbert E, Strom P, Gerke QN. Infliximab\u2019s influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model. BMC Surg. 2014;14:23.","journal-title":"BMC Surg"},{"issue":"3","key":"698_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/micr.20197","volume":"26","author":"SK Thompson","year":"2006","unstructured":"Thompson SK, Chang EY, Jobe BA. Clinical review: healing in gastrointestinal anastomoses, part I. Microsurgery. 2006;26(3):131\u20136.","journal-title":"Microsurgery"},{"issue":"3","key":"698_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.suc.2009.03.006","volume":"89","author":"P Teller","year":"2009","unstructured":"Teller P, White TK. The physiology of wound healing: injury through maturation. Surg Clin North Am. 2009;89(3):599\u2013610.","journal-title":"Surg Clin North Am"},{"issue":"5","key":"698_CR6","first-page":"E33","volume":"59","author":"S Koh","year":"2016","unstructured":"Koh S, Zaghiyan K, Fleshner P. Safety and efficacy of the perioperative use of vedolizumab in medically refractory IBD patients. Does \u201cgut-specificity\u201d impact surgical morbidity? Dis Colon Rectum. 2016;59(5):E33.","journal-title":"Dis Colon Rectum"},{"issue":"5 Suppl 1","key":"698_CR7","doi-asserted-by":"publisher","first-page":"S581","DOI":"10.1016\/S0016-5085(17)32096-6","volume":"152","author":"M Ferrante","year":"2017","unstructured":"Ferrante M, Schils N, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D\u2019Hoore A. Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto) colectomy with ileal pouch-anal anastomosis. Gastroenterology. 2017;152(5 Suppl 1):S581\u20132.","journal-title":"Gastroenterology"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/ajg.2017.201","volume":"112","author":"A Yamada","year":"2017","unstructured":"Yamada A, Komaki Y, Patel N, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskil K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol. 2017;112:1423\u20139.","journal-title":"Am J Gastroenterol"},{"key":"698_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjw147","volume":"11","author":"AL Lightner","year":"2017","unstructured":"Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, Dozois EJ, Loftus EV. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis. 2017;11:185\u201390.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"698_CR10","first-page":"E33","volume":"69","author":"S Stringfield","year":"2016","unstructured":"Stringfield S, Parry L, Sandborn WJ, Ramamoorthy S, Eisenstein S. Patients on vedolizumab have a high rate of postoperative complications. Dis Colon Rectum. 2016;69(5):E33.","journal-title":"Dis Colon Rectum"},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ibd\/izx076","volume":"24","author":"AL Lightner","year":"2018","unstructured":"Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfiled S, Hudesman D, Remzi F, Loftus EV Jr. Postoperative outcomes in vedolizumab treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study. Inflamm Bowel Dis. 2018;24:871\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"698_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/17474124.2015.975208","volume":"9","author":"K Zaghiyan","year":"2015","unstructured":"Zaghiyan K, McGovern D, Fleshner P. Should biologic agents be stopped before surgery for inflammatory bowel disease? Expert Rev Gastroenterol Hepatol. 2015;9(3):269\u201372.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"698_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):849\u201353.","journal-title":"Gut"},{"issue":"2","key":"698_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-0038-1676471","volume":"32","author":"H Kunitake","year":"2019","unstructured":"Kunitake H. Enhanced recovery after surgery for colorectal surgery. Clin Colon Rectal Surg. 2019;32(2):93\u20134.","journal-title":"Clin Colon Rectal Surg"},{"issue":"12","key":"698_CR15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1097\/MIB.0000000000001248","volume":"23","author":"AL Lightner","year":"2017","unstructured":"Lightner AL, McKenna NP, Moncrief S, Pemberton JH, Raffals LE, Mathis KL. Surgical outcomes in Vedolizumab-treated patients with ulcerative colitis. Inflamm Bowel Dis. 2017;23(12):2197\u2013201.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"698_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/ecco-jcc\/jjx095","volume":"11","author":"M Ferrante","year":"2017","unstructured":"Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D\u2019Hoore A. Perioperative use of Vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohns Colitis. 2017;11(11):1353\u201361.","journal-title":"J Crohns Colitis."},{"issue":"5","key":"698_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00384-017-2789-5","volume":"32","author":"F Grass","year":"2017","unstructured":"Grass F, Slieker J, Jurt J, Kummer A, Sol\u00e0 J, Hahnloser D, Demartines N, H\u00fcbner M. Postoperative ileus in an enhanced recovery pathway-a retrospective cohort study. Int J Color Dis. 2017;32(5):675\u201381.","journal-title":"Int J Color Dis"},{"issue":"1","key":"698_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/gut.2007.131870","volume":"57","author":"R De Giorgio","year":"2008","unstructured":"De Giorgio R, Barbara G. Evidence for mast cell involvement in human postoperative ileus: a novel link. Gut. 2008;57(1):5\u20137.","journal-title":"Gut"},{"issue":"1","key":"698_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/gut.2007.120238","volume":"57","author":"RJ Bennink","year":"2008","unstructured":"The FO, Bennink RJ, Ankum WM, Buist MR, Busch OR, Gouma DJ, van der Heide S, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut. 2008;57(1):33\u201340.","journal-title":"Gut"},{"issue":"9","key":"698_CR20","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/ajg.2009.268","volume":"104","author":"MR Buist","year":"2009","unstructured":"The FO, Buist MR, Lei A, Bennink RJ, Hofland J, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol. 2009;104(9):2257\u201366.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"698_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0016-5085(03)00883-7","volume":"125","author":"FN Aberra","year":"2003","unstructured":"Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320\u20137.","journal-title":"Gastroenterology"},{"issue":"8","key":"698_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/MIB.0000000000000780","volume":"22","author":"A Afzali","year":"2016","unstructured":"Afzali A, Park CJ, Zhu K, Hu JK, Sharma P, Sinanan MN, Lee SD. Preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1887\u201395.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"698_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/40.4.375","volume":"40","author":"AS Williams","year":"2001","unstructured":"Williams AS, Topley N, Dojcinov S, Richards PJ, Williams BD. Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology (Oxford). 2001;40(4):375\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"698_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11938-017-0120-8","volume":"15","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Sabol T, Vaziri H. Update on the use of biologic therapy in ulcerative colitis. Curr Treat Options Gastroenterol. 2017;15(1):155\u201367.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"2","key":"698_CR25","first-page":"159","volume":"20","author":"EA Frost","year":"2009","unstructured":"Frost EA. Preventing paralytic ileus: can the anesthesiologist help. Middle East J Anaesthesiol. 2009;20(2):159\u201365.","journal-title":"Middle East J Anaesthesiol"},{"issue":"9","key":"698_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/bjs.4640","volume":"91","author":"NS Abraham","year":"2004","unstructured":"Abraham NS, Young JM, Solomon MJ. Meta-analysis of short-term outcomes after laparoscopic resection for colorectal cancer. Br J Surg. 2004;91(9):1111\u201324.","journal-title":"Br J Surg"},{"issue":"9320","key":"698_CR27","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/S0140-6736(02)08711-1","volume":"359","author":"DN Lobo","year":"2002","unstructured":"Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002;359(9320):1812\u20138.","journal-title":"Lancet"},{"issue":"7","key":"698_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10350-004-6672-4","volume":"46","author":"CP Delaney","year":"2003","unstructured":"Delaney CP, Zutshi M, Senagore AJ, Remzi FH, Hammel J, Fazio VW. Prospective, randomized, controlled trial between a pathway of controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection. Dis Colon Rectum. 2003;46(7):851\u20139.","journal-title":"Dis Colon Rectum"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-020-00698-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12893-020-00698-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-020-00698-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T19:09:07Z","timestamp":1614884947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-020-00698-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1186\/s12893-020-00698-8","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The surgery was a standard procedure, and the patient was well informed of the operation risk. The patient was informed that treatment results are included in study analysis while patient\u2019s personal information will not be shared. Study was approved by the Cedars-Sinai Medical Center IRB (#3358).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}